_edited.png)
What Is an OTC Drug and the Role of OTC Monographs in the United States
- Daniel Jiménez
- 1 day ago
- 5 min read
Updated: 3 hours ago
The United States represents one of the largest markets for over-the-counter (OTC) medicines globally, offering significant opportunities for companies developing non-prescription therapeutic products.
Understanding what qualifies as an OTC drug, how OTC monograph’s function, and what regulatory obligations apply is essential for companies planning to enter the U.S. market.
Table of Contents
What Is an OTC Drug?
An over-the-counter (OTC) drug is a medicine that can be sold directly to consumers without a prescription from a healthcare professional and are regulated by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act.
Unlike cosmetics or dietary supplements, OTC products are legally classified as drugs, meaning they must meet specific standards for:
Safety
Effectiveness
Quality
Labeling
Manufacturing controls
Two Regulatory Pathways for OTC Products
In the United States, OTC drugs can reach the market through two primary regulatory routes:
1. OTC Monograph Pathway (Most Common)
Products marketed under an FDA monograph do not require individual product approval if they comply with established conditions.
These conditions include:
Permitted active ingredients
Dosage levels and formulations
Labeling statements and warnings
Indications and claims
Directions for use
Monographs essentially function as a regulatory “rulebook” for categories of OTC drugs.
2. New Drug Application (NDA)
If a product does not fit within an existing monograph — for example, due to a novel ingredient or new therapeutic claim, the company must pursue a full New Drug Application (NDA), similar to prescription drugs.
Most international companies entering the OTC market use the monograph pathway due to its lower regulatory burden.
What Are OTC Monographs?
OTC monographs are regulatory documents issued by the FDA that define the conditions under which OTC drugs are considered:
Generally Recognized as Safe and Effective (GRASE): If a product complies with an applicable monograph, it can be marketed without prior FDA approval.
Categories Covered by OTC Monographs
Monographs exist across many therapeutic areas, including:
Sunscreen drug products
Topical antimicrobial products
External analgesics
Acne drug products
Antifungal treatments
Skin protectants
Oral healthcare products
Antiperspirants
Cough, cold, and allergy medicines
Each category has specific requirements that must be followed precisely.
The Role of Claims in OTC Compliance
Claims are one of the most critical aspects of OTC regulatory compliance.
Unlike cosmetics, where claims are largely marketing-driven, OTC claims must:
Align with the applicable monograph
Follow approved wording structures
Include mandatory warnings
Reflect authorized indications
Companies cannot create new therapeutic claims outside monograph conditions without regulatory authorization.
Claims strategy is therefore not only a marketing decision but also a regulatory constraint.
Overview of the OTC Registration Process
While OTC drugs under monographs do not require product approval, companies still must complete several regulatory steps before marketing.
These typically include:
Establishment registration with FDA
Drug product listing
NDC assignment
Labeling compliance verification
Manufacturing compliance (cGMP)
Safety documentation
Post-market obligations
The process involves multiple FDA systems and identifiers, and coordination between manufacturers, brand owners, and regulatory representatives.
OMUFA User Fees: What Companies Must Know
The Over-the-Counter Monograph User Fee Program (OMUFA) funds FDA oversight of OTC monograph drugs.
OMUFA includes two main types of fees:
Facility Fees
Annual fees paid by facilities that manufacture or process finished OTC monograph drugs.
These fees apply to both U.S. and foreign facilities.
OMOR Fees
Fees paid when companies request changes to OTC monographs, such as new ingredients or indications.
User fees help support FDA review timelines and regulatory activities related to OTC products.
The program is authorized for multiple fiscal years and continues to evolve through legislative updates.
Companies often underestimate the financial planning required for OMUFA compliance.
Registration Fees vs OMUFA Fees
It is important to distinguish OMUFA fees from other regulatory costs.
Companies may encounter:
Facility registration costs
Regulatory consulting costs
Manufacturing compliance costs
Testing and validation costs
U.S. Agent services
OMUFA fees specifically relate to FDA oversight of OTC monograph drugs.
Understanding which entities are responsible for paying which fees is essential in OEM and contract manufacturing models.
The Role of the U.S. Agent for Foreign OTC Companies
Foreign drug establishments must designate a U.S. Agent when registering with the FDA.
The U.S. Agent:
Serves as FDA’s communication contact in the United States
Facilitates regulatory correspondence
Supports coordination during inspections or questions
However, the U.S. Agent does not assume regulatory responsibility for product compliance unless contractually defined.
Manufacturing Compliance: cGMP Requirements
OTC drugs must be manufactured in compliance with FDA drug Good Manufacturing Practices (cGMP).
These requirements are significantly more stringent than cosmetic GMP expectations and may include:
Quality systems and documentation
Validation processes
Stability programs
Laboratory controls
Batch records
Complaint handling and recalls
Foreign manufacturers must be prepared for FDA inspections.
Common Challenges in OTC Market Entry
Across international projects, several recurring issues appear:
Misclassification between cosmetics and OTC drugs
Incorrect assumptions about monograph applicability
Underestimating GMP requirements
Claims that exceed monograph conditions
Lack of clarity regarding regulatory ownership
Confusion about FDA identifiers and registration steps
These challenges often lead to delays or compliance risks.
Why OTC Regulatory Strategy Is More Complex Than It Appears
At first glance, OTC products marketed under monographs may appear easier than prescription drugs.
However, successful compliance requires alignment across multiple regulatory dimensions.
OTC regulation sits at the intersection of drug law and consumer health products, making it uniquely complex.
OTC drugs represent a major opportunity in the U.S. healthcare market, offering accessible treatment options for consumers without prescriptions.
The OTC monograph system provides a pathway to market without individual product approval, but compliance still requires careful planning, regulatory expertise, and strategic decision-making.
Understanding monographs, user fees, claims limitations, and registration obligations is essential for companies seeking successful entry into the U.S. OTC sector.
If your company is planning to commercialize OTC products in the United States or needs support navigating FDA requirements, Belab Services can assist you.
Our regulatory specialists support international companies with:
OTC regulatory strategy and classification
Monograph assessment and compliance evaluation
FDA establishment registration and drug listing
NDC assignment and labeling review
OMUFA compliance support
U.S. Agent services
End-to-end market entry strategy
Comments